Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large decline in short interest in October. As of October 15th, there was short interest totalling 100 shares, a decline of 99.1% from the September 30th total of 11,600 shares. Based on an average trading volume of 89,700 shares, the days-to-cover ratio is currently 0.0 days.

Bioxytran Stock Performance

Shares of OTCMKTS BIXT traded down $0.03 during trading hours on Friday, hitting $0.09. The stock had a trading volume of 205,633 shares, compared to its average volume of 84,780. The firm’s 50-day moving average price is $0.10 and its two-hundred day moving average price is $0.11. The company has a market capitalization of $15.15 million, a P/E ratio of -2.85 and a beta of -0.89. Bioxytran has a 52 week low of $0.07 and a 52 week high of $0.18.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.